GYRE
What one share of Gyre Therapeutics holds
Pharmaceutical Preparations
In this section, unless otherwise specified, references to “we,” “our,” “us” and “our company” refer to Gyre Therapeutics, Inc. and our majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.) (“Gyre Pharmaceuticals”).
Gyre Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.02 |
|---|---|
| Profit | −$0.19 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.06 |
| Cash and investments | $0.41 |
| Book value | $1.02 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$21.75 | $0.60 | −$24.31 | — | $20.04 |
| 2017 | — | −$7.45 | $0.01 | −$5.83 | — | $5.06 |
| 2018 | — | −$2.68 | $0.03 | −$2.58 | — | $10.03 |
| 2019 | — | −$4.60 | $0.01 | −$3.64 | — | $5.68 |
| 2020 | $1.09 | −$2.93 | — | −$2.87 | — | $3.44 |
| 2021 | $0.24 | −$2.87 | $0.03 | −$2.76 | — | $1.31 |
| 2022 | $1.35 | $0.03 | $0.07 | $0.08 | $0.24 | $0.67 |
| 2023 | $1.72 | −$1.41 | $0.13 | $0.26 | — | −$0.21 |
| 2024 | $1.03 | $0.05 | $0.02 | −$0.06 | — | $0.73 |
| 2025 | $1.13 | $0.02 | $0.01 | −$0.00 | — | $0.68 |